Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $9.00 Average PT from Brokerages

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.00.

SNTI has been the subject of a number of research reports. Leerink Partnrs upgraded Senti Biosciences to a “strong-buy” rating in a report on Friday, November 21st. Chardan Capital raised their target price on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Leerink Partners assumed coverage on Senti Biosciences in a report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price target for the company. HC Wainwright began coverage on Senti Biosciences in a research report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen raised Senti Biosciences to a “sell” rating in a research report on Saturday, December 13th.

Senti Biosciences Trading Down 4.1%

Shares of SNTI opened at $1.17 on Tuesday. Senti Biosciences has a twelve month low of $1.15 and a twelve month high of $5.10. The firm has a market capitalization of $30.76 million, a P/E ratio of -0.35 and a beta of 2.08. The stock’s fifty day simple moving average is $1.89 and its 200 day simple moving average is $1.90.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Sell-side analysts predict that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Trading of Senti Biosciences

Large investors have recently bought and sold shares of the company. Armistice Capital LLC purchased a new stake in shares of Senti Biosciences during the second quarter valued at approximately $1,883,000. Nantahala Capital Management LLC acquired a new stake in Senti Biosciences during the 1st quarter valued at $2,984,000. Heights Capital Management Inc. purchased a new stake in Senti Biosciences during the 1st quarter worth $2,520,000. Geode Capital Management LLC lifted its holdings in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Senti Biosciences in the 3rd quarter worth $117,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.